2 recruiting, 1 completed, 1 terminated, 1 unknown. 5 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Recruiting 2, Completed 1, Terminated 1, Unknown 1 |
| Phase 3 | 1 | Unknown 1 |
Follow CKD: new trials by email Literature Review of CKD trials Research Report on CKD
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Mechanistic Study on the Effect of HTD1801 Versus Placebo on Kidney Function in Patients With Type 2 Diabetes and Chronic Kidney Disease. HTD1801, placebo - T2DM, CKD | Phase 2 | Recruiting | Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences | 75 | 2026-07-09 | 2026-07-15 |
| Comparative Study on the Mode of Action of Vicadrostat and Spironolactone on Protein Profiles and Renal Hemodynamic Effects (COMPARE-VS) vicadrostat / empagliflozin combination 1, Spironolactone (drug) - CKD, Cardiovascular Diseases | Phase 2 | Recruiting | University Medical Center Groningen | 100 | 2026-05-12 | 2026-05-29 |
| A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes Retatrutide, Placebo - Overweight or Obesity, CKD | Phase 2 | Completed | Eli Lilly and Company | 146 | 2023-07-20 | 2025-11-25 |
| Dapaglifozin to Avoid Acute Kindey Injury (AKI) to Chronic Kidney Disease (CKD) Transition: DAKI-CKD Study Dapagliflozin - AKI - Acute Kidney Injury, Biomarkers | Phase 2 / Phase 3 | Unknown | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | 100 | 2023-01-01 | 2024-03-05 |
| The ORTIZ Study: Optimising RASi Therapy With SZC Sodium Zirconium Cyclosilicate, Placebo - CKD, Diabetes Mellitus, Type 2 | Phase 2 | Terminated | Barts & The London NHS Trust | 18 | 2022-06-17 | 2025-06-08 |
Diabetes Mellitus, Type 2 (2) · Acute Kidney Injury (1) · Cardiovascular Diseases (1) · Heart Failure (1) · Hyperkalemia (1) · Obesity (1) · Overweight (1)
Diabetes Mellitus (2) · Endocrine System Diseases (2) · Glucose Metabolism Disorders (2) · Metabolic Diseases (2) · Nutritional and Metabolic Diseases (2) · Body Weight (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Heart Diseases (1) · Kidney Diseases (1) · Male Urogenital Diseases (1) · Nutrition Disorders (1) · Overnutrition (1) · Pathological Conditions, Signs and Symptoms (1) · Renal Insufficiency (1)
Pharmaceutical Preparations (1) · Spironolactone (1) · dapagliflozin (1) · retatrutide (1) · sodium zirconium cyclosilicate (1)
Barts & The London NHS Trust (1) · Eli Lilly and Company (1) · Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences (1) · Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran (1) · University Medical Center Groningen (1)
United Kingdom (2) · Canada (1) · China (1) · Italy (1) · Mexico (1) · Netherlands (1) · Spain (1) · United States (1)
Jiandong Jiang (1) · Keiran McCafferty (1) · Lulu Wang (1)
2023 (1), 2025 (1)